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Abstract
Researchers have begun investigating whether insulin mimetics such as ZnCl2
could promote bone healing in both non-diabetic and diabetic fracture healing similarly to
insulin. Our research focused on understanding the mechanism by which ZnCl2 affects
chondrogenesis, an important component of bone fracture healing. The increases in
proteoglycan deposition and cell proliferation seen in our data may be a result of ZnCl2
induction of the IGF-1 pathway. When the VEGF pathway was inhibited in ZnCl2- or
insulin-treated cells significant decreases in proteoglycan deposition occurred on day 7
and 14 (P=0.007 for ZnCl2, P=0.028 for insulin) when compared to controls. This data
suggests that in the presence of VEGF that Runx1 may be an important mediator in
ZnCl2- mediated chondrogenesis. We believe that ZnCl2 may be upregulating many
members of the collagen family and BMP-6 which insulin is not. Our data demonstrates
that at later timepoints, VEGF inhibition produces higher amounts of genes such as jun,
grb2, and cyclin D1 which were identified in the NGS data and confirmed through
QPCR. Although the mechanisms by which ZnCl2 and insulin have been shown to
overlap, our data suggests that ZnCl2 works through a mechanism different then insulin
when employing the VEGF- pathway.

Keywords: bone, fracture healing, chondrogenesis, endochondral ossification, zinc
chloride, ZnCl2, insulin, vascular endothelial growth factor, VEGF
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Introduction
Diabetes is a disease that affects the metabolism of almost 9.4% of the American
population (American Diabetes Association, 2018). Patients afflicted with diabetes
typically have delayed or failed bone healing (Graves et. al, 2011). As a result, many
studies have focused on developing therapeutics or medicine that could improve diabetic
bone fracture healing. A subset of these studies has identified insulin and insulin
mimetics such as Zinc Chloride (ZnCl2) as possible therapeutics which can help improve
diabetic bone healing (Gandhi et. al, 2005; Wey et. al, 2014; Ovesen et. al, 2001).
Although the positive role insulin plays on fracture healing is relatively well understood,
the mechanism by which insulin mimetics like ZnCl2 promote bone formation is unclear.
Therefore, this study aims to characterize the mechanism by which the insulin mimetic
ZnCl2 affects chondrogenesis, an important process of bone development and repair.
Bone Development
Bone development is crucial to the survival of multicellular organisms with a
skeletal system. Deletion of key genes involved in skeletal development prevents or
reduces the viability of the organisms’ offspring. Cbfa1 (core-binding factor a1) is a
transcription factor that signals mesenchymal cells to differentiate into osteoblasts. In
fact, Cbfa1 null mice die quickly upon birth and are unable to convert their precursor
cartilaginous skeleton into bone (Komori et. al, 1997). Bone development begins when
the somite lineage gives rise to the axial skeleton, next the lateral plate mesoderm lineage
gives rise to the limb skeleton, and finally the cranial neural crest generates the cartilage
branchial arch and craniofacial bones (Gilbert SF, 2000). Primary bone formation occurs
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through a process of intramembranous ossification. Intramembranous ossification
involves the direct formation of bone from mesenchymal cells, with no cartilage
intermediate. Secondary bone formation or endochondral ossification occurs when
mesenchymal stem cells (MSCs) become cartilage cells and form the bony frame of
cartilage.
Endochondral ossification is initiated when mesenchymal stem cells are
committed to becoming chondrocytes. Two paracrine transcription factors, Pax1 and
Scleraxis aid this transition by stimulating genes specific to chondrocyte differentiation
(Sosic et. al, 1997; Cserjesi et. al, 1995). The Sry-homeobox 9 (SOX9) gene is another
important gene expressed in the pre-cartilaginous condensations of MSCs. Without
SOX9 expression, humans can develop campomelic dysplasia, a rare and severe bone
disorder that affects most bones throughout the body. This condition causes a weakening
of the cartilage, which especially affects the upper respiratory tract, a condition called
laryngotracheomalacia (NIH- Campomelic dysplasia, 2014; Wright et. al, 1995). Liao et
al. demonstrates that Sox9 can mediate bone morphogenic protein-2 (BMP-2) induced
MSC differentiation into chondrocytes and promote the formation a cartilaginous skeletal
precursor (Liao et. al, 2014). During this process the perichondrium is invaded by
capillaries and it is transformed into the periosteum (Wang et. al, 2017). Chondrocytes in
the area differentiate, swell, and become hypertrophic. Chondrocytes become
hypertrophic due to many factors, two of which include a change in respiration
metabolism and a secretion of membrane-bound vesicles. When chondrocyte respiration
changes from aerobic to anaerobic, partly due to creatine kinase, it leads to an altered
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mitochondrial energy potential, an altered cell metabolism, and hypertrophy (Shapiro et.
al, 1992).
Chondrocytes that have undergone hypertrophy secrete membrane-bound vesicles
into the matrix of the fracture site; these vesicles release enzymes that generate a
molecular cocktail of calcium phosphate that is rich in acid-phosphate, annexin V, lipid
mediators, and signaling proteins. Once released, these molecules aid in mineralization of
the cartilage matrix (Wu et. al, 1997). Following hypertrophy, chondrocytes undergo
tumor-necrosis factor alpha (TNF-α) induced apoptosis which leads to cartilage matrix
mineralization, characterized by collagen X and fibronectin deposition (Bruder and
Caplan, 1989). Macrophage colony stimulating factor (M-CSF), osteoprotegerin (OPG),
tumor necrosis factor alpha (TNF-α), and receptor activator of nuclear factor kappa B
ligand (RANKL) stimulate the resorption of the mineralized cartilage; during this time,
RANKL, M-CSF, and OPG are thought to help bone cells create woven bone
(Gerstenfeld et. al, 2003). The vasculature that is formed allows for precursor osteoblasts
to migrate into the bone forming region. Once mineralized, blood vessels penetrate the
bone site, and osteoblasts utilize the cartilage scaffold to form new bone (Gilbert SF,
2000). A summary of the gene and proteins influencing endochondral ossification during
bone development is shown in Figure 1. (Goldring et. al, 2006).
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Figure 1: Sequence of events during the development of long bones (Goldring et. al,
2006). In this figure, the major protein and gene interactions are shown as corresponding
to the stage of the bone development process. As bones develop, first the mesenchyme
proliferates and condenses due to genes that include sonic hedgehog (SHH), transforming
growth factor β (TGF-β), and Sox9. The proteins involved in this stage include collagens
I, IIA, and XI. When chondroprogenitor cells begin to proliferate and differentiate into
chondrocytes, insulin like growth factor 1 (IGF1), bone morphogenetic proteins 2,4,7,14
(BMP-2,4,7,14), and Sox9,5,6 are active. Hyaluronan and collagens IIB, IX, and XI are
active in this stage. The protein aggrecan is made in this stage and continues into
chondrogenesis and chondrocyte hypertrophy. Runt transcription factor x2 (Runx2),
BMP2,7, fibroblast growth factor (FGF18, FGFR3), Indian hedgehog, and junD are
involved in chondrogenesis and hypertrophy. Vascular endothelial growth factor
(VEGF), runx2, FGF2, FGFR1, osterix, and β-catenin are among the major genes
involved in vascular invasion and cartilage mineralization. The proteins involved here are
solely collagen X, indicating bone is beginning to become finalized. In the final
ossification stage, gene transcription to aid the fracture healing is reduced significantly
and collagen I and osteocalcin are the major proteins used to completely heal the bone.
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Fracture Healing
Most fractures heal through secondary bone healing and progress through distinct
phases including inflammation and hematoma formation, soft tissue callus formation,
callus mineralization, and bone remodeling. Day 0-3 involves initial hematoma and
inflammation with monocytes, T-cells, macrophages, polymorphonuclear neutrophils
(PMN or granulocytes), and B-cells. Day 3-5 involves the hematoma stage but the bone
marrow stem cells (BMSCs) are the major mediator. Through the help of osteoblasts and
chondrocytes, days 5-10 are characterized by a soft callus with unmineralized cartilage.
Days 10-16 involve chondrocyte hypertrophy and osteoclasts that form the fibrous bone
tissue. During days 16-21, hematopoietic cells and myelopoietic cells are active that form
hard callus, also known as secondary bone. With the aid of osteocytes, days 21-35
finalize the fracture healing process into remodeled bone (Wang et. al, 2017).
Immediately following fracture, inflammation floods the site of damage and leads
to hematoma formation. The hematoma is comprised of blood cells and bone marrow
cells including macrophages, B cells, and T cells, coagulating in response to
inflammation. This coagulation provides a scaffold for the soft tissue callus to form
around (Gerstenfeld et. al, 2003). Cells of the primary inflammatory response secrete
many proinflammatory molecules including TNF-α, interleukin-1 (IL-1), IL-6, and IL-11.
These molecules encourage angiogenesis and spur the influx of more inflammatory cells
to the site of the fracture (Sfeir et. al, 2005). TNF-α is expressed by these inflammatory
cells, leading to chemotaxis of other required cells such as neutrophils, macrophages, B
cells, and T cells (Zhang et. al, 2009). In addition, IL-1 secreted by macrophages induces
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IL-6 production in osteoblasts, elevates angiogenesis at the fracture, and aids in the
construction of the primary cartilage callus (Kon et. al, 2001). Secretion of IL-6 can
stimulate angiogenesis, the production of VEGF, and allow osteoclasts and osteoblasts to
differentiate (Yang et. al, 2007). IL-11 has been shown to increase bone formation and
prevent cortical bone loss, as well as increase osteoblast differentiation in the presence of
BMP-2 (Takeuchi et. al, 2002).
The recruitment of mesenchymal stem cells is crucial to fracture healing and is
stimulated by many factors including SDF-1, CXCR4, TGF-B, BMPs, and Runx2
(Granero-Molto et. al, 2009). Data has demonstrated a relationship between stromal cell
derived factor 1 (SDF-1) and CXCR4, the G-protein coupled receptor of SDF-1 exists.
These factors work together to regulate the influx of mesenchymal stem cells to the site
of trauma. When SDF-1 was overexpressed in a methylprednisolone induced
osteonecrosis femoral head rat model, fracture healing was improved due to an increase
in osteogenesis and angiogenesis (Yang et. al, 2018). Data has also shown that only
mesenchymal stem cells that express the CXCR4 receptor can navigate themselves to the
fracture callus (Kitaori et. al, 2009). BMP-7, and other BMPs, are also thought to
orchestrate the recruitment of bone progenitor cells to the fracture; BMP-2 has been
shown to be crucial for osteogenesis but does not have a role in osteogenic cell
recruitment (Bais et. al, 2009).
Once the mesenchymal cells are recruited many of them differentiate into
chondrocytes and begin producing, collagen I and collagen II in the matrix. The TGF-β
superfamily, specifically TGF-β2 and β3, as well as GDF-5 are of high importance in the

6

chondrogenesis and endochondral ossification (Cho et. al, 2002). TGF-β has been shown
to stimulate mesenchymal stem cells to proliferate and differentiate into chondrocytes
early in the fracture healing process (Joyce et. al, 1990). Runt transcription factor
isoform 2 (Runx2) is a major regulator of chondrocyte proliferation and differentiation
during endochondral ossification. Runx2 null mice are unable to undergo endochondral
ossification necessary for bone formation and result in nonviable offspring (Chen et. al,
2014). Mice that were specifically floxed for a deletion of Runx2 in Runx2ΔE8/ΔE8 mice
were unable to produce mature chondrocytes or vasculature (Chen et. al, 2014). Runx2 is
a direct regulator of genes controlling the cell cycle, including cyclin A1 and c-Myb
which has been linked to its ability to regulate the proliferation of chondrocytes (Chen et.
al, 2014).
Once chondrocytes become hypertrophic, they express Osterix (Osx) and being
to produce copious amounts of VEGF; this leads to a recruitment of chondroclasts into
the fracture site (Carlevaro et. al, 2000). In studies, where exogenous VEGF was added
during fracture repair, healing improved (Peng et. al, 2002). When Sprague-Dawley rats
received TNP-470, a VEGF inhibitor, their unilateral closed femoral fractures resulted in
non-unions due to the lack of vasculature from the inhibitor; uninhibited rats did not have
adverse fracture healing. Another study involved a cylindrical defect being drilled into
Sprague-Dawley rats and an adenoviral vector was added to encode VEGF; the other
animals received no intervention. Healing was promoted in the animals that received the
VEGF treatment and their bone mineral content was also enhanced over the non-treated
control mice; VEGF treated mice in this experiment also completed the endochondral
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phase of bone development faster. (Keramaris et. al, 2008). VEGF null mice also have
delays in blood vessel invasion surrounding the center of primary ossification and delays
in removing terminally differentiated chondrocytes from the bone formation site
(Berendsen and Olsen, 2014). The role of VEGF in bone healing may also be enhanced
through interactions with other pro-angiogenic factors including the BMP family
(Deckers et. al, 2002).
In bone repair, new bone must be formed by osteoblasts and old bone must be
resorbed and remodeled by osteoclasts. The Wnt family can stimulate mesenchymal
stem cells to differentiate into osteoblasts as well as spur on osteoblasts to form new bone
(Chen et. al, 2009). VEGF has been shown to influence the function of both osteoblasts
and osteoclasts. At the location of the bone damage, VEGF was seen along the new
trabeculae but not inside the cells inside of the bone, demonstrating that osteo-lineage
cells, including osteoblasts, are crucial producers of VEGF that is necessary to heal
cortical damage. A 3D-reconstruction of injured bone showed significantly decreased
amounts of mineralized tissue in VEGF-deficient mutants. Osteoblasts from VEGFA
knock-out mice had reduced mineralization in culture when compared with
controls. VEGF expression on hypertrophic chondrocytes causes monocytes to
differentiate into osteoclasts. Also, osteoblast-secreted VEGF allows neutrophils to enter
during the acute inflammatory stage (Hu and Olsen, 2016). Once the cartilage is replaced
by bone, it is remodeled to increase the stability of the bone. The hard callus is remodeled
into lamellar bone with a central cavity, the medulla. The process of remodeling bone is
a balance between depositing bone by osteoblasts and resorbing the hard callus by
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osteoclasts which is primarily influenced by IL-1, RANKL, and TNF-α (Wendeberg,
1961).

VEGF pathway
VEGF is a signaling molecule that is important for many processes such as
vasculogenesis, angiogenesis, and bone repair. VEGF has been identified as a key
paracrine agent in vasculogenesis (Carmeliet et. al). VEGF promotes angiogenesis, leads
to a rise in permeability of the vasculature, and facilitates the modification of the
extracellular matrix (Hoeppner et. al). AP-1 (activator protein 1) is a transcription factor
that is responsible for proliferation, increased gene expression, and tumor progression.
Overexpression of both mTOR (mammalian target of rapamycin) and AP-1 increase the
transcriptional and protein levels of vascular endothelial growth factor. An increase in
VEGF leads to improved bone healing. Cottrell et al. demonstrated using an in vitro
chondrocyte cell model that ZnCl2 treatment affected mTOR gene expression suggesting
that this insulin mimetic may exert its affect by modulating VEGF expression or
associated pathways (Burgess and Cottrell, 2017). The TGF (transforming growth
factors) family of signaling molecules are known to induce transcription of many genes,
including VEGF. TGF-B induces VEGF gene expression through Smad proteins, which
encourage transcription through binding with DNA-binding proteins. Hypoxia also
greatly increases this property of TGF-B (Sanchez-Elsner T et. al) which is commonly
exists during early fracture repair.
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Insulin is a widely studied signaling molecule that can increase VEGF’s gene
expression through its relationship with the HIF-1a (hypoxia inducible factor) and ARNT
(aryl hydrocarbon receptor nuclear translocator) complex. Insulin and insulin growth
factor-1 (IGF-1) can stabilize the hypoxia response element, increase the expression of
Glut1, a glucose transporter (Zelzer et. al) and lead to the overexpression of HIF-1a
which stimulate an increase in the release of growth factors IGF-2, IGFBP-2, and IGFBP3. These have an important role in bone formation and chondrogenesis as they are
directly related to the insulin pathway that improves bone formation (Feldser et. al).
Vegfafl/flOsx-Cre/ZsG mice have a decrease in bone marrow-released neutrophils during
the acute phase of inflammation, due to a deleted VEGFA gene (Hu and Olsen, 2016).
This data suggests a mechanism by which osteoblast generated VEGF facilities
neutrophil proliferation and activation which are cells important to bone processes
including chondrogenesis (Hu and Olsen, 2016).

Insulin Signaling and chondrogenesis
Insulin signaling is a crucial component of chondrogenesis as well as other stages
of the bone healing process (Vardatsikos et. al, 2013). Insulin is a hormone that
influences the metabolism of bone and fracture healing, among many physiological
phenomena. The insulin receptor is a family of receptor tyrosine kinase signaling proteins
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that are transmembrane. This family includes the classical insulin receptor and insulinlike growth factor receptors 1 and 2.

Figure 2: Insulin receptor and the major signaling pathways used in tissue repair (Hrynyk
et. al, 2014). This figure depicts the three major outcomes of the canonical insulin
receptor and the pathway mediators that are utilized. When insulin binds to the insulin
receptor, SHC binds to Grb2, allowing SOS to activate the Ras pathway. Ras activates
Raf, which activates MEK, which activates ERK1/2, allowing for tissue growth and
repair. When insulin binds to the insulin receptor, IRS1/2 allows for PI3K to activate
PDK, which activates Akt. Akt activation allows for direct biomacromolecule synthesis.
Akt activation also allows for GLUT4 activation, which increases glucose uptake. This
increase in glucose levels provides the cell with the energy to repair the damaged tissue.
The classical insulin receptor is constructed as a pro-receptor and then is cleaved
to form a hetero-tetrameric receptor. This receptor is composed of two alpha subunits and
two beta subunits, linked in a β-α-α-β configuration by disulfide linkages; the receptor
has two monomers, each with one alpha and one beta subunit (Bravo et. al, 1994). The
alpha subunits are the extracellular domain and the beta subunits contain the
transmembrane domain, the tyrosine kinase domain, an ATP binding site, and a tyrosine
auto phosphorylation site (Fantl et. al, 1993). In the course of insulin receptor activation,
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insulin binds to one of the two binding sites on each of the monomers, named sites 1 and
2. When insulin binds to site 1, cross linking occurs that allows site 2 to be available for
binding, which allows the receptor to be activated (Becker and Rother, 1990). Usually the
alpha subunit blocks the ability of the B subunit to auto-phosphorylate, but once insulin is
bound the alpha subunit cannot achieve this blocking; therefore, the kinase activity of the
beta subunit can now trans-phosphorylate, change its conformation, and increase its
kinase potential. The classical insulin receptor and IGF-1 receptors can produce
functional hybrid receptors, demonstrating why IGF-1 and classical insulin can interact
with the other’s receptor (Patti and Kahn, 1998).
Once receptor dimerization occurs, signal transduction can ensue. This begins
with phosphorylation of tyrosines located on intracellular B- subunits on the insulin
receptor. These phospho-tyrosines are not able to function as a docking site. This permits
the Src homology and collagen (SHC) protein to bind to the kinase through their Srchomology-2 domains. This signal is now continued through growth factor receptor bound
protein 2 (Grb2), son of sevenless (SOS), and Ras. Ras then propagates the signal
through Raf, MEK, and ERK. ERK, and finally can translocate into the nucleus. Once
inside the nuclear membrane, ERK can cause the cell to proliferate. This signaling
pathway has an effect that aids in wound healing and tissue repair, including bone
fracture healing (Saltiel and Kahn, 2001).
The activation of the insulin receptor also stimulates glucose uptake and the
synthesis of biomacromolecules, which are crucial in facilitating tissue repair. Once
tyrosines are phosphorylated, insulin receptor substrates 1 and 2 can bind to the receptor
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and propagate signal transduction through the PI3K/phosphoinositide dependent protein
kinase (PDK)/Akt pathway. This allows for the breakdown of fats and creation of
glycogen and structural proteins, aiding in repairing tissue damage and providing energy
for cell proliferation. The activated Akt pathway also aids in glucose uptake due to
glucose transporter type 4, GLUT4 (Pessin and Saltiel, 2000). Phospho-Akt can also lead
to increased blood flow, angiogenesis, and cell survival through endothelial nitric oxide
synthase, eNOS (Lima et. al, 2012). Insulin’s effect on wound healing is still not fully
elucidated, but the literature demonstrates that the insulin signaling can orchestrate
biomacromolecule procurement and tissue regeneration (Hrynyk et. al, 2014).
Poor diabetic fracture healing is postulated to stem from decreased insulin
signaling, which plays critical roles in signal transmission from glucose uptake to tissue
repair and growth (Jiao et. al, 2015). Several studies have concluded that localized insulin
administration can enhance fracture healing in both diabetic and non-diabetic animals
(Paglia et. al, 2013). In an in-vivo murine load-bearing defect model, injected with
insulin an increase in osteoblast number was found with a concomitant increase in
osteoid area (Dedania et. al, 2011). Insulin treatment in vitro has been demonstrated to
stimulate chondrocyte proliferation and differentiation. More specifically, gene
expression of collagen 2a1 and glycosaminoglycan were upregulated, demonstrating
insulin’s ability to increase chondrocyte differentiation and proliferation (Iwata et. al,
2010). Lee et al also demonstrated that local insulin treatment increased mineralization at
4 and 6 weeks using an osteotomy model (Lee and Pilch, 1994). Rat osteoblasts have
also been shown to have functional insulin receptors that increase collagen production
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when activated by insulin in vitro (Cornish et. al, 1996). Finally, Mueller’s study in
mesenchymal stem cells demonstrates that glycosaminoglycan production increased in a
dose-dependent manner after insulin treatment (Mueller et. al, 2013). These data
demonstrate that insulin is a regulator of chondrogenesis and collagen production during
bone healing.

Zinc and Chondrogenesis
Zinc chloride (ZnCl2) treatment has been demonstrated to aid in bone healing
(Vardatsikos et. al, 2013). An insulin mimetic is a substance that gives an insulin-like
effect but does not lead to the fat buildup the insulin causes. Zinc is stored in the pancreas
just like insulin which encouraged the idea initially that it was an insulin mimetic
(Howell et. al, 1969). ZnCl2 was determined to be an insulin mimetic in 1980 when an
experiment demonstrated its ability to mimic insulin’s ability to increase fat production in
rat adipocytes (Sakurai et. al, 2002). Zinc can function as an intracellular signaling
molecule and it has a role in many processes including growth and development (Tudor
et. al, 2005). Zinc can enhance the phosphorylation of tyrosine kinases, which includes
the classic insulin receptor, insulin-like growth factor type-1 and 2 receptors (IGF1R and
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IGF2R, Figure 2).

Figure 3: The potential mechanism for the insulin-like effects of zinc (Vardatsikos et. al,
2013). Zinc is a divalent ion that can enter the cell through the lipid membrane. It causes
increased activation of tyrosine phosphatases, which lead to end gene upregulation of
ERK1/2 and PKB/Akt.
Zinc elicits this effect partly through causing a rise in reactive oxygen species that
lead to an increase activation of tyrosine phosphatases, which further phosphorylates
tyrosines on protein tyrosine kinases. Activated protein tyrosine kinases then
phosphorylate downstream targets including substrates of the insulin receptor, which can
lead to activation of the MAPK/ERK signaling pathway as well as the phosphoinositide 3
kinase (PI3K)/protein kinase B (PKB)/AKT signaling pathway. The ERK pathway leads
to an increase in gene transcription, cell growth, and hypertrophy. The PKB/AKT
pathway, based on its downstream targets, which include mammalian target of rapamycin
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(mTOR) and forkhead box protein O1 (FOXO1), causes an increase in protein synthesis,
cell cycle progression, cell survival, gluconeogenesis, lipid metabolism, glycogen
synthesis, and glucose transport (Vardatsikos et. al, 2013). Zinc regulation has also been
demonstrated partially to be controlled by metallothionein proteins. The role of
metallothioneins in zinc-induced differentiation and proliferation has been related to
modulation of second messenger metabolism, cellular signal recognition, protein
phosphatase and kinase activity, and the ability to stimulate or inhibit transcription
factors (Beyersmann and Haase, 2001).
Many forms of zinc have been shown to affect bone healing responses both in
vitro and in vivo. For instance, ZnCl2 has been shown to activate phospho-AKT and
promote chondrocyte maturation in the ATDC5 in vitro chondrocyte cell model (Burgess
and Cottrell, 2017). ZnSO4 treatment also increased the number of vascular endothelial
cells through the lipoxygenase pathway, which operates through endogenous basic FGF.
This leads to a better bone healing outcome, due to more vasculature, which accelerates
the fracture healing process (Kaji et. al, 1994). While zinc calcium sulfate treatment
increased bone density as measured with by microCT in a rat spinal fusion model
(Koerner et. al, 2016). In a Wistar rat model, ZnCl2 local release through a calcium
sulfate carrier has been shown to enhance chondrogenesis through histologic analysis
(Krell et. al, 2017). Zinc acexamate was shown to significantly increase the amount of
IGF-1 and TGF-β over control, further demonstrating the impact that zinc compounds
have on enhancing fracture healing (Igarashi and Yamaguchi, 2001). The mechanism by
which ZnCl2 and other zinc compounds have on enhancing fracture healing in diabetic
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and non-diabetic is unclear (Sakurai et. al, 2002). Further research to determine this
mechanism is warranted.

Hypothesis and purpose
The overall purpose of this research is to investigate the molecular mechanism by
which the insulin mimetic, zinc chloride elicits positive effects on chondrogenesis. More
specifically, the below research hypothesizes that zinc chloride treatment increases
VEGF expression in chondrocytes which enhances their proliferation and function.
These positive effects on chondrogenesis could contribute to the enhanced healing seen in
zinc chloride treated fracture healing models.

Materials and Methods
Cell Culture Methods
ATDC5 cells were utilized for this project as they are a chondrogenic cell line.
They are utilized in research to demonstrate and model how chondrocytes differentiate.
They were originally isolated from the AT805 teratocarcinoma cell line of differentiating
stem cells.
ATDC5 cells were grown in growth media, containing DMEM/F12 50:50
(Dulbecco’s Modification of Eagle’s Media) supplemented with 5% fetal bovine serum
and 1% penicillin-streptomycin, glutamate, transferrin, and selenium. The cells were
grown in a 37°C & 5% CO2 incubator.
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RNA Isolation and Quantification
Confluent ATDC5 cells were placed in growth media supplemented with 1ug/mL
insulin, 0uM zinc chloride, or 100uM ZnCl2 to stimulate differentiation. Cells were
treated for 24 hours and RNA was collected with a RNeasy Mini Kit (Qiagen, Hilden,
Germany) using the manufacturer’s directions. Quality and quantity of RNA was
determined using a BioDrop spectrophotometer (BioDrop, Cambridge, United Kingdom).
The RNA concentration was determined by 260 nm absorbance and calculated by the
BioDrop device. The RNA quality was verified using the 260/280 absorbance ratio.
Samples of these calculations can be found in Table 1 in Appendix. A sample calculation
of RNA quality is shown below:
Sample Name and Timepoint: Growth Media 1 Day 4. A260 = 0.359. A280= 0.176.
A260/A280 = 2.040.
An aliquot of resulting RNA was separated by gel electrophoresis in a 1% agarose
gel made with 3-morpholinopropane-1-sulfonic acid (MOPS) buffer and diethyl
pyrocarbonate (DEPC) RNase free water. The gel underwent electrophoresis at 90V for 1
hour and stained with either SYBR GreenGlo (ThermoFisher Scientific, Waltham,
Massachusetts) or ethidium bromide (0.1 ug/ml). The gel was then visualized on a Protein
Simple FluorChem E machine (Protein Simple, San Jose, California) under the SYBR
Green settings and an image was captured. Only RNAs with acceptable characteristics
including RNA bands located at 16S (900 bases) and 28S (1800 bases) ribosomal RNA
were used for further analysis in RNA Deep Sequencing or Quantitative Real Time
Polymerase Chain Reaction (PCR).
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RNA Deep Sequencing & Data Generation
Total RNA isolates were purified to isolate the mRNA fraction using a GeneRead
Pure mRNA kit by Qiagen (Qiagen, Hilden, Germany) following the manufacturer’s
instructions. The purified mRNA was quantified afterwards using the BioDrop
spectrophotometer (BioDrop, Cambridge, United Kingdom) and sent to the Molecular
Research Facility (MRF) at Rutgers Newark for RNA Deep Sequencing (Rutgers
University- Newark Campus, Newark, NJ).
At the MRF the samples were purified and quantified, as needed prior to
sequencing. Sequencing was completed using an Illumina NextSeq 500 (Illumina, San
Diego, California). NGS data was received and analyzed in CLC Genomics Workbench
by aligning raw reads to an updated Mus musculus reference genome, GRCm38 (NCBI
GRC). Samples were run on a High flow cell at a 1x75bp configuration. RPKM
normalized gene expression values and fold changes (between all treatment groups) were
determined for each gene and 1-way analysis of variance (1-way ANOVA) was utilized
to determine any statistical differences between treatment groups, where significance was
determined by a P<0.05. Graphical plots were created for these in SigmaPlot 13 (Systat
Software, San Jose, California).
Ingenuity Pathway Analysis (IPA) by Qiaqen (Qiagen, Hilden, Germany) was
used to predict pathway regulators based on fold gene expression changes amongst the
treatment groups. The transformed RPKM (reads per kilobase per million) value of
insulin was normalized against the transformed RPKM of growth media by the
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𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑒𝑑 𝑅𝑃𝐾𝑀 𝑖𝑛𝑠𝑢𝑙𝑖𝑛

ratio 𝑡𝑟𝑎𝑛𝑑𝑓𝑜𝑟𝑚𝑒𝑑 𝑅𝑃𝐾𝑀 𝑔𝑟𝑜𝑤𝑡ℎ 𝑚𝑒𝑑𝑖𝑎 and the transformed RPKM of ZnCl2 was normalized
the same way. Once these normalized ratios were derived, a core analysis was conducted
separately for both ZnCl2 and insulin treatment groups. Each treatment group had effector
networks and association networks created for their data set.
Once the core analyses were completed, a comparison analysis was run to
compare the two treatment groups. The comparison analysis then took the transformed
RPKM ratios for both insulin and ZnCl2 and overlaid them onto canonical pathways to
determine which treatment had a significant increase or decrease in the utilization of that
specific pathway. The pathways and their fold change increase or decrease, in Z score
format, was compared and a −2 ≥ 𝑍 ≥ 2 was considered significant by the program.
These Z scores can be found in results Table 3. Three selected canonical pathways were
chosen to develop RT-qPCR targets, as they were differing with statistical significance
between the two treatment groups and had overlaps between the pathways: VEGF Family
Ligand-Receptor Interactions, IGF-1 Signaling, and GM-CSF signaling. The Ingenuity
Pathway Analysis for GM-CSF signaling can be found in Appendix 3.

Real Time-quantitative PCR
RNA isolation
All RNA isolates were prepped as described previously under RNA isolation and
quantification.

20

Reverse Transcription
RNA was then reverse transcribed (RT) to complementary deoxyribonucleic acid
(cDNA). For each reaction, 1ug of RNA, 500uM dNTPs (Thermofisher, Waltham,
Massachusetts), 5uM oligo(dT) primer (Thermofisher, Waltham, Massachusetts), and
deionized water were combined in a 20ul reaction. The contents were mixed and
centrifuged down. The tubes were placed on a 65°C for 3 minutes to disrupt secondary
structures and then returned to ice to prevent renaturing of RNA molecules. Next, 2uL of
10X RT Buffer (250mM Tris-HCl, 375mM KCl, 15mM MgCl2, 50mM DTT) (Promega,
Madison, Wisconsin), 1uL units of RNAseOUT RNase inhibitor (Thermofisher,
Waltham, Massachusetts) and 1uL of MM-LV reverse transcriptase enzyme (Promega,
Madison, Wisconsin) were added to the RT reactions and incubated at 42°C for 1 hour.
After the 60 minutes incubation, the RT reactions were inactivated by heating at 95°C for
10 minutes. The tubes were then stored in a -20°C freezer.
PCR Procedure
PCR was used to confirm that the reverse transcription procedure successfully
produced cDNA. A total volume of 25uL for each PCR reaction was achieved by adding
2.5uL of cDNA template, 2.5uL of 10X Taq buffer (1X in reaction: 10mM Tris-HCl,
50mM KCl, 1.5mM MgCl2, pH 8.3 @ 25℃) (New England BioLabs, Ipswich,
Massachusetts), 2.5uM of each primer, 2uL of 5mM dNTPs (Thermofisher, Waltham,
Massachusetts), 14.5uL of deionized (DI) water (Millipore Sigma, Darmstadt, Germany),
and 1uL of Taq DNA polymerase enzyme (New England BioLabs, Ipswich,
Massachusetts). The amount of endogenous cDNA template utilized in the PCR was
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derived from 0.1ug of total RNA from the RT reaction. The reaction was run using a
forward primer GAGCTGAACGGGAAGCTCACTGG and a reverse primer
TCCACCACCCTGTTGCTGTAGCC of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) primer set and using the conditions below on T100 Thermacycler (Applied
Biosystems ThermoFisher, Waltham, Massachusetts).
1) 95°C hold for 5 minutes
2) 40 cycles of 95°C denaturation for 30 seconds, 57°C annealing for 30 seconds,
and 72°C elongation for 30 seconds
3) 72°C final hold for 10 minutes.
An aliquot of the PCR product was mixed with 5ul loading dye and separated on a
2% agarose gel was made with 1X tris-borate-EDTA buffer (TBE) to ensure integrity of
the cDNA and the ability of the cDNA made in each RT reaction to be amplified by PCR.
The gels were stained with ethidium bromide (0.1ug/ml), visualized, and photographed
on a Protein Simple Fluorchem E machine (Protein Simple, San Jose, California). Only
samples with the appropriate single cDNA band located at the correct corresponding
weight were used for further analysis.
qPCR
The previously discussed verified PCR products then underwent qPCR to
determine gene expression for each treatment groups; they were run to optimize
temperature for each primer set. The primers for each gene were developed by Integrated
DNA Technologies’ Primer Design Tool for 2 primers and an intercalating dye
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(Integrated DNA Technologies, Coralville, Iowa). The primer sets and annealing
temperature used for qPCR can be found in Table 1.
Gene Name

Primer Set

Annealing
Temperature (Tm)
(℃)

GAPDH

F- ACCACAGTCCATGCCATCAC

55℃

R- TCCACCACCCTGTTGCTGTA
VEGFA

55℃

FTGGTTCTTCACTCCCTCAAATC
RGGTCTCTCTCTCTCTTCCTTGA

Jun

55℃

FCCAGACTGTACACCAGAAGATG
RCAACCAAAGTGTCTGCTTTCC

Grb2

57.8℃

FCTGTCCGTCAAGTTTGGAAATG
RCTTCACCACCCACAGGAAATA

Sox9

57.8℃

FCCTGGACTGTATGTGGATGTG
RTAAGGTCTGTCCGATGTCTCT

Runx1

F- CAGAGAGGTGCCAAGGATTT

55℃

R- CCCTGACCAACAGCTTACTT
Cycd1

57.8℃

FCAGAGGCGGATGAGAACAAG
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RGAGGGTGGGTTGGAAATGAA
Runx2

F- TGGCTTGGGTTTCAGGTTAG

55℃

RGGTTTCTTAGGGTCTTGGAGTG
VEGFC

57.8℃

FCCACGTGAGGTGTGTATAGATG
R- CGGACACACATGGAGGTTTA

Fos

54℃

FATTGTCGAGGTGGTCTGAATG
RTCGAAAGACCTCAGGGTAGAA

GMCSF

54℃

FCCAGTTCTTGGAAGGGCTTATT
R- TGGAATCTCCTGGCCCTTAT

Grb10

57.8℃

FCCCAGAAAGTCTGCTACATACC
R- GCTGTCAACCATGGCAAATC

VEGFR2

60.1℃

FGCGGAGACGCTCTTCATAATA
RGACAAGAAGGAGCCAGAAGAA

Table 1: qPCR primer sets and annealing temperatures
For each qPCR reaction, 25uL of volume was created as follows: 12.5uL of Fast
SYBR Green Master Mix (2X), (ThermoFisher, Waltham, Massachusetts), forward and
reverse primer at a final concentration of 70nM, diluted cDNA template, and distilled
water. Reactions were performed using an Applied Biosystems 7500 real-time
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quantitative PCR instrument (Applied Biosystems ThermoFisher, Waltham,
Massachusetts) and below thermal cycling conditions.
1) 95°C hold for 15 minutes
2) 40 cycles of denaturing 95°C for 30 seconds, annealing at Tm (°C) determined
by primers (found in Table 1) for 30 seconds, and
3) elongation at 72°C for 30 seconds.
Each reaction yielded amplification plot and a melting curve. The amplification plot
yielded a CT, or cycle threshold, where the signal became greater than the noise and the
gene expression could be verified. Each reaction’s melt curve was analyzed to ensure one
specific peak. GAPDH was used as the researcher’s control gene, as it is constitutively
expressed in every cell, a housekeeper gene. Data was normalized in SigmaPlot 13
(Systat Software, San Jose, California). The method for normalizing the data was derived
from Schmittgen et. al’s 2008 paper, which can be found in the references. The
researcher compared the 2-ΔC(T) values of the growth media control, insulin treated, and
zinc treated groups by 1-way ANOVA with a P<0.05 significance cutoff. Statistically
significant genes were graphed with SigmaPlot 13(Systat Software, San Jose, California)
and included in the results section.
Glacial Blue Assay
The Glacial Blue assay, also known as the Alcian Blue assay, is utilized to
determine cell proliferation rate by staining the total amount of sulfated
glycosaminoglycans. Cells were seeded at density of 50,000cells/well in a 24-well tissue
culture treated plate. Once cells were confluent, media was switched to 1ug/mL insulin,
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100uM ZnCl2, growth media and axitinib (VEGFR inhibitor) (Pfizer, New York City,
NY), 1ug/mL insulin and axitinib, 100uM ZnCl2 and axitinib, or kept in growth media.
Treatments were run in triplicate.
Cells were grown for 4 days, 7 days, 10 days, or 14 days and media was changed
as necessary. On the specified time point, cell media was removed, and the plates were
washed twice with 1X Hank’s Buffered Saline Solution (HBSS) (Thermofisher,
Waltham, Massachusetts). Cells were fixed, by adding 100% cold methanol to the plate
for 5 minutes. Next, the methanol was removed, and the cells were stained overnight with
0.1% Alcian Blue in 0.1M HCl. The cells were then washed three times with 1X HBSS
and 300uL of 6M guanidine HCl was added to each well for 24 hours. The absorbance of
each plate was read at 595nm on a Molecular Devices SpectraMax M5 spectrophotometer
(Molecular Devices, San Jose, California). Absorbance values were used for analysis by
1-way ANOVA and an image of the plate was taken. Absorbance values were then
normalized against growth media, the negative control, in order to produce fold changes
that were then graphed.

MTT Assay
CO2 incubator, counted, and then plated at 10,000cells/well in a 96 well tissue
culture treated plate. The cells were left in the wells overnight to adhere to the bottom of
the well. Cells were then treated with 1ug/mL insulin, 100uM ZnCl2, growth media and
axitinib (VEGFR inhibitor), 1ug/mL insulin and axitinib, 100uM ZnCl2 and axitinib, or
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kept in growth media. Treatments were run in triplicate and media was changed as
necessary. Cells were grown for 1 day, 4 days, 7 days, or 10 days after treatment.
At the specified time point, 10uL of 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) reagent (MTT= 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) was added to each of the wells for at least 4 hours, until
intracellular purple crystals were seen under the microscope. After incubation, the media
and MTT reagent mixture was aspirated off and 100uL of dimethyl sulfoxide (DMSO)
was added to each of the wells to be analyzed. After the addition of DMSO, the plate was
incubated for 2 hours at room temperature and kept in the dark to protect it from light.
Once the 2 hours was completed, the plate underwent spectrophotometric analysis on a
Molecular Devices SpectraMax M5 spectrophotometer (Molecular Devices, San Jose,
California) and the absorbance for the wells was recorded at 570nm. Absorbance values
were collected, and an image of the plate was taken. Absorbance values were then
converted to cell proliferation values with the following formula:
𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑔𝑟𝑜𝑢𝑝 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑣𝑎𝑙𝑢𝑒
𝑔𝑟𝑜𝑤𝑡ℎ 𝑚𝑒𝑑𝑖𝑎 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑣𝑎𝑙𝑢𝑒

× 100%. The cell proliferation values were then analyzed

by 1-way ANOVA and a graphical output was obtained.
Data and Statistical Analysis
Graphing and statistical analysis of data between groups was completed using
SigmaPlot 13 (SyStat Software, San Jose, California) and appropriate ANOVA and posttesting hoc Holm-Sidak tests.
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Results

Figure 4: Differential gene expression of ZnCl2-Treated ATDC5 chondrogenic cells 24
hours post-treatment. A) Bone Morphogenetic Proteins (BMPs) B) Collagens C) Jun
Family D) Runx family E) Sox Family F) Transforming Growth Factor (TGF)
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Superfamily. Each bar graphs compares the transformed reads per kilobase per million
(RPKM) of each gene in each treatment group. Statistical significance (P<0.05) is
denoted each graph and was determined using 1-way ANOVA testing.
For the BMP genes, only BMP6 was found to have a statistically significant
difference in RPKM between the treatment groups. ZnCl2 treatment significantly
elevated BMP-6 expression by 664% over insulin and 364% over growth media (Figure
4A, Table 2). ZnCl2 treatment significantly elevated the expression of all collagens when
compared to media and insulin except for col7a1. The highest percentage increases were
in collagen17a1, collagen8a1, collagen ec11, and collagen6a5; collagen6a5 had the
highest increase overall for all collagen genes. Collagen17a1 was 96% higher than
insulin and 66% elevated over growth media when treated with ZnCl2. When
supplemented with ZnCl2, Collagen8a1 had an increase of 54% and 56% over growth
media and insulin, respectively. ZnCl2 treated Collagen ec11 expression was 350% and
502% elevated over insulin and growth media, respectively. Collagen6a5’s expression
when treated with ZnCl2 was elevated by 418% in comparison to insulin and 646% when
compared to growth media. In the case of col7a1, ZnCl2 treated gene expression was
significantly decreased as compared to insulin and media only groups. Collagen7a1
expression was 24% lower than growth media and 24% lower than insulin when treated
with ZnCl2 (Figure 4B).
For jun and junb, both insulin and ZnCl2 were elevated over growth media by
22% and 82%, respectively; ZnCl2 was elevated over insulin by 48% for both genes as
well. In the case of jund, insulin had no significant deviation from growth media.
However, ZnCl2 treated jund expression was elevated by 46% over both growth media
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and insulin (Figure 4C). For the Runx family of genes, both insulin and ZnCl2 treatment
groups had a significant increase in gene expression of runx3 by 80% over the negative
control, growth media. In the case of runx1, only ZnCl2 had any statistical significance
when compared with insulin or growth media (Table 2). ZnCl2 treated ATDC5 cells
caused an increase in runx1 gene expression of 59% over insulin and 81% over growth
media (Figure 4D).
In the SOX gene family, both SOX9 and SOX13 are upregulated significantly
when ZnCl2 treated over growth media while only SOX13 has an upregulation
significantly over insulin. For SOX9, ZnCl2 expression is 67% over growth media. For
SOX13, ZnCl2 expression is 207% over growth media and 139% over insulin (Figure
4E). For the TGF family of genes, four were demonstrated to show a statistically
significant difference in RPKM, as depicted in Figure 4F. ZnCl2 expression was
significantly elevated over both growth media and insulin for TGF-B1 (66% over insulin,
75% over growth), TGF-BR3 (45% over insulin, 55.5% over growth), and TGIF-1 (33%
over insulin, 28% over growth). For TGF-α, ZnCl2’s expression was only elevated over
growth media, at a 58% increase (Figure 4F, Table 2).
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Figure 5: Differential gene expression of ZnCl2-Treated ATDC5 chondrogenic cells 24
hours post-treatment. A) Vascular Endothelial Growth Factor (VEGF) Family B) Colony
Stimulating Factor (CSF) C) Cyclin D family D) Grbs E) Hedgehog F) IGFs. Each bar
graphs compares the transformed reads per kilobase per million (RPKM) of each gene in
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each treatment group. Statistical significance (P<0.05) is denoted each graph and was
determined using 1-way ANOVA testing.
For the VEGF family of genes, three were demonstrated to show a statistically
significant difference in RPKM, as depicted in the above graphic. ZnCl2 and insulin both
had elevated gene expression of VEGFA and VEGFB above growth media, 68% and
56% for VEGFA and 58% and 38% for VEGFB respectively. ZnCl2 expression was
significantly elevated over both growth media (265%) and insulin (143%) for flt1, a
specific pattern only seen in zinc-treated chondrocytes (Figure 5A). For the CSF genes,
only Csf1 was demonstrated to show a statistically significant difference in RPKM.
ZnCl2 and insulin expression was significantly elevated over both growth media, 45%
and 32% respectively (Figure 5B, Table 2).
ZnCl2 expression was significantly elevated when compared to growth media by
300% for cyclin D1, demonstrating a different genetic mechanism in the ATDC5 cell line
when treated with ZnCl2 at the 1-day time point as compared to insulin. When ATDC5
cells were exposed to ZnCl2, the gene expression values for cyclin D2 and D3 were 108%
and 29% higher than growth media, respectively; insulin treated cells also had this same
response, with D2 being 139% elevated and D3 being 37% elevated respectively. In the
case of cyclin D binding partner 1, insulin gene expression was decreased by 22% as
compared to growth media and ZnCl2 expression was 24.5% increased over insulin
(Figure 5C). For the Grb genes, only Grb2 was demonstrated to show a statistically
significant difference in RPKM. ZnCl2 had 101.4% increased gene expression over no
treatment, growth media, and insulin had 57% elevation above growth media (Figure
5D).
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For the Notch Signaling genes, only desert hedgehog (DHH) was demonstrated to
show a statistically significant difference in RPKM. ZnCl2 expression was significantly
elevated over both growth media and insulin, 371% and 142% respectively,
demonstrating a different genetic mechanism in the ATDC5 cell line when treated with
ZnCl2 at the 1-day time point as compared to insulin (Figure 5E). In relation to growth
media, IGF-1 expression was decreased by 46% when treated with insulin; ZnCl2
expression was elevated by 132% as compared to insulin. When treated with ZnCl2, IGFbinding partner 2 was 233% elevated over insulin. ZnCl2 treatment significantly
increased gene expression of IGF-bp4 over insulin by 317% and growth media by 318%.
Insulin treatment increased IGF2bp2 expression by 8.7% over growth media; ZnCl2
treatment increased this gene’s expression by 130% over insulin and 150% over growth
media (Figure 5F, Table 2).
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Table 2: Statistically Significant P-Values in the Next Generation Sequencing
Experiment. This table contains the statistically significant results of the 1-way ANOVA
that was ran on the corrected absorbance values of each treatment group in the Next
Generation Sequencing experiment. The table shows the timepoint, the treatments being
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compared, the difference of the means, the t score, the P value, and if the P value is less
than 0.05, the statistical significance threshold. The letter G signifies growth media, the
letter I signifies insulin, and Z signifies ZnCl2.

Figure 6: Comparison analysis of gene expression values overlaid onto the VEGF Family
Ligand-Receptor Interactions pathway. A) Z score table visualization B) canonical
pathway. For A, an orange color indicates a slight upregulation of the pathway and a
deeper orange is a strong upregulation of the pathway; a blue color indicates a slight
downregulation of the pathway and a deep blue is a strong downregulation of the
pathway. A dot in B demonstrates that the result is not statistically significant, where Z is
greater than -2 and below 2. A pink color in B indicates slight up-regulation of a gene and
a deeper red indicates higher gene expression. A slight green color in B indicates a slight
downregulation of the gene and a deep green color indicates high gene downregulation.

In Figure 6, both insulin and ZnCl2 expression values for the genes in the VEGF
canonical pathway were compared by Ingenuity Pathway Analysis. This canonical
pathway is included as it demonstrates a direct result from the NGS experiment that
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shows ZnCl2 is utilizing the VEGF pathway in a different mechanism than Insulin treated
ATDC5 cells. ZnCl2 treated ATDC5 chondrocytes have a higher Z score for the VEGF
Family Ligand-Receptor Interactions than insulin, as shown in A, where ZnCl2 has a
deeper orange. This means that the IPA program utilizes the gene expression values from
ZnCl2, compares them to the expected gene values from their algorithm and literature
database, and produces the canonical pathway results with those values from their
analysis.
The values here in Figure 6B are red, indicating that the expression value of
ZnCl2-treated chondrocytes is significantly higher in this pathway than the expression
values of insulin-treated chondrocytes as well as being higher than the canonically
accepted values. VEGFA-C and VEGFR1-2 are a deep red color, indicating that this
pathway is being highly upregulated. c-fos and grb2 downstream are also slightly
upregulated.
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Figure 7: Comparison analysis of gene expression values overlaid onto the IGF-1
Signaling pathway. A) Z score table visualization B) canonical pathway. For A, an
orange color indicates a slight upregulation of the pathway and a deeper orange is a
strong upregulation of the pathway; a blue color indicates a slight downregulation of the
pathway and a deep blue is a strong downregulation of the pathway. A dot in B
demonstrates that the result is not statistically significant, where Z is greater than -2 and
below 2. A pink color in B indicates slight up-regulation of a gene and a deeper red
indicates higher gene expression. A slight green color in B indicates a slight
downregulation of the gene and a deep green color indicates high gene downregulation.
In Figure 7, both insulin and ZnCl2 expression values for the genes in this
canonical pathway were compared by Ingenuity Pathway Analysis. The researchers have
delved into the IGF-1 canonical pathway because it confirms the NGS experiment results
that show ZnCl2 is employing the IGF-1 signaling pathway differently than Insulin
treated ATDC5 cells. ATDC5 chondrocytes treated with ZnCl2 have a significantly
elevated Z score for the IGF-1 signaling pathway than insulin, as shown in A; this is
demonstrated by ZnCl2 having a deeper orange color. Therefore, IPA utilizes the gene
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expression values from ZnCl2, compares them to the expected gene values from their
algorithm and literature database, and produces the canonical pathway results with those
values from their analysis. c-fos, c-jun, and grb2 in B are red, meaning that the gene
expression values of ATDC5 chondrocytes treated with ZnCl2 are significantly higher in
this pathway than the expression values of insulin-treated chondrocytes, as well as being
higher than the canonically accepted values. grb10 is green, which indicates a decreased
gene expression pattern. grb10 in this pathway leads to the blocking of IGF-R1, marked
with a slash through as indicated by the blue arrow.
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Table 3: Canonical Pathway output for Insulin and Zinc Chloride treated ATDC5 cells at
24 hours post-treatment. Shown are Z scores of the expression pattern of insulin and zinc
chloride treated ATDC5 chondrocytes from IPA’s comparison analysis on the gene
expression values comparing insulin and ZnCl2. A Z score in this output is a statistical
measure of similarity between the expected gene expression relationship direction and the
observed gene expression values; scores greater than 2 or below negative 2 are
statistically significant in this output. A Z score below negative 2 demonstrates a
statistically significant predicted inhibition of that pathway; a Z score above 2 means that
there is a statistically significant predicted activation of the pathway.
In this study, NGS data analysis demonstrated that VEGF, GM-CSF, and IGF-1
signaling were significantly differentially regulated when comparing ZnCl2 and insulin
treatment groups (Zzinc chloride > Zinsulin). Therefore, our research focused on understanding
the importance of VEGF in ZnCl2 mediated chondrogenesis.
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Figure 8: Proteoglycan Deposition Measured in Treated ATDC5 Cells Overtime. Fold
changes in absorbance values for each treatment group when normalized to growth media
are shown. A fold change below 1 depicts a decreased amount of proteoglycan deposition
as compared to growth media, the negative control. A fold change greater than 1 depicts
an increase in proteoglycan deposition when compared to the negative control. Statistical
significance was determined on the corrected absorbance values of each sample.

At day 7, Axitinib treatment significantly reduced proteoglycan deposition in both
ZnCl2 and insulin treated ATDC5 chondrocytes (Figure 8, Table 4). The Insulin+Axitinib
and ZnCl2+Axitinib groups were both significantly lower than growth media, insulin, and
ZnCl2 in terms of proteoglycan deposition. Insulin+Axitinib’s proteoglycan deposition
was 20.5% lower than growth media, 25% lower than insulin, and 21.7% lower than
ZnCl2 at day 7. ZnCl2 and Axitinib’s proteoglycan deposition was 25.3% lower than
growth media, 29.6% lower than insulin, and 26.4% lower than ZnCl2 at day 7. On day
10, insulin treatment produced the highest amount of proteoglycan deposition. Insulin
was significantly elevated over the Insulin+Axitinib, ZnCl2, and ZnCl2+Axitinib. Insulin
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had higher proteoglycan deposition over Insulin+Axitinib by 51.1%, ZnCl2 by 61.8%,
and ZnCl2+Axitinib by 63.1%. For day 14, insulin again produced the highest levels of
proteoglycan deposition. Insulin’s proteoglycan deposition was significantly higher than
growth media+Axitinib, Insulin+Axitinib, ZnCl2, and ZnCl2+Axitinib. Insulin was 79.8%
elevated over growth media+Axitinib, 51.9% over Insulin+Axitinib, 75.2% over ZnCl2,
and 105.6% over ZnCl2+Axitinib. (Figure 8, Table 4)

Table 4: Statistically Significant P-Values of Proteoglycan Deposition Quantitation
between groups. This table contains the statistically significant results of the 1-way
ANOVA that was ran on the corrected absorbance values of each treatment group. The
table shows the timepoint, the treatments being compared, the difference of the means,
the t score, the P value, and if the P value is less than 0.05, the statistical significance
threshold.
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Figure 9: Cell Proliferation Measured through the MTT Assay in Treated ATDC5 Cells.
Shown is cellular proliferation value for each treatment group was normalized to growth
media to produce fold changes. A fold change below 1 depicts a decreased amount of
proteoglycan deposition as compared to growth media, the negative control. A fold
change greater than 1 depicts an increase in proteoglycan deposition when compared to
the negative control. Statistical significance was determined on the cellular proliferation
values of each sample.
At day 4, insulin and Axitinib treated ATDC5 cells have the highest cellular
proliferation values of any treatment group (Figure 9, Table 5). Insulin+Axitinib’s
cellular proliferation is 126% greater than growth media, 92% greater than ZnCl2, and
82% greater than ZnCl2+Axitinib. ZnCl2+Axitinib’s cellular proliferation is 34% less
than Insulin and 44% less than Insulin+Axitinib. Insulin’s cellular proliferation is 94%
greater than growth media and 56% greater than growth media and Axitinib. ZnCl2 had
39% less proliferation than insulin. For day 10, the insulin and Axitinib treatment group
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once again had the highest cellular proliferation values. ZnCl2+Axitinib had a decreased
cellular proliferation of 54% as compared to Insulin+Axitinib. Insulin+Axitinib had
increased cellular proliferation over growth media by 114% and 67% greater than ZnCl2.

Table 5: Statistically Significant P-Values in Cellular Proliferation. This table contains
the statistically significant results of the 1-way ANOVA that was ran on the cellular
proliferation values of each treatment group in the MTT Assay. The table shows the
timepoint, the treatments being compared, the difference of the means, the t score, the P
value, and if the P value is less than 0.05, the statistical significance threshold.
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Real Time PCR

44

Figure 10: Gene Expression measured with Real-Time Quantitative PCR in Treated
ATDC5 Cells. A) VEGFA B) Runx2 C) Jun D) Grb2 E) CycD1 F) Grb10 G) VEGFR2
H) SOX9 I) Runx1. Gene expression cycle threshold (CT) values were converted to
2−𝛥𝐶𝑇 values for each treatment group. These 2−𝛥𝐶𝑇 values were normalized to growth
media to produce fold changes. A fold change below 1 depicts a decreased amount of
gene expression as compared to growth media, the negative control. A fold change
greater than 1 depicts an increase in gene expression when compared to the negative
control. Statistical significance was determined on the 2−𝛥𝐶𝑇 values of each sample.

45

46

Table 6: Statistically Significant P Values from Real Time Quantitative PCR Experiment.
This table contains the statistically significant results of the 1-way ANOVA that was ran
on the corrected absorbance values of each treatment group in the Real Time Quantitative
PCR Experiment. The table shows the timepoint, the treatments being compared, the
difference of the means, the t score, the P value, and if the P value is less than 0.05, the
statistical significance threshold.
VEGFA expression at the 4-day timepoint demonstrated that Insulin+Axitinib
was 374.3% elevated over growth media, 251.6% increased as compared to insulin, and
215% above Growth+Axitinib. ZnCl2+Axitinib- treated VEGFA gene expression was
176.3% above growth media at the same timepoint. Gene expression of the runx2 gene at
4 days was significantly upregulated in Insulin+Axitinib treated ATDC5 cells by 313.1%
over insulin and 216% over growth media. Runx2 at 7 days had more treatment groups
have statistically different gene expression values. Growth+Axitinib was 164.6%
increased over growth media, 249.2% over ZnCl2, and 121.9% above insulin.
ZnCl2+Axitnib had gene expression 146.4% above growth media, 106.6% over insulin,
225.1% over ZnCl2, and 36% below Insulin+Axitinib. Insulin+Axitinib- treated gene
expression was increased by 284.7% over growth media, 407.6% over ZnCl2, 222.5%
over insulin, and 45.4% over Growth+Axitinib.
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Jun gene expression in treated ATDC5 chondrocytes only had statistically
significant differential gene expression at the 7-day timepoint. Insulin+Axitinib at this
timepoint had gene expression 90% over insulin, 110.4% over growth media, and 437.5%
over ZnCl2. Growth+Axitinib gene expression was 341.7% increased above ZnCl2; jun
gene expression in ZnCl2+Axitinib-treated chondrocytes was 325% above ZnCl2. Grb2’s
gene expression values at day 1 demonstrated that ZnCl2 treatment increased grb2
expression by 135% over ZnCl2+Axitinib and 159.3% over growth. At 4 days, the only
statistically significant differential gene expression in grb2 was Insulin+Axitinib being
133% over insulin. Statistically significant differential gene expression for grb2 at 7 days
had solely ZnCl2 being 81.3% below Insulin+Axitinib.
Cyclin D1 gene expression at day 1 only yielded one statistically significant
result: ZnCl2 was elevated over ZnCl2+Axitinib by 140.3%. For day 4, ZnCl2-treated
cycD1 gene expression was 292.4% above growth media and 156.8% over insulin. Grb10
gene expression at 4 days yielded results that Insulin+Axitinib expression for this gene is
172.1% elevated over growth media, 164.6% over insulin, 148.4% over
Growth+Axitinib, and 96.9% over ZnCl2. ZnCl2+Axitinib gene expression for grb10 at 4
days is 69.5% below Insulin+Axitinib. At 7 days, grb10 gene expression had numerous
statistically significant differential gene expressions. Insulin+Axitinib was elevated by
567% over insulin, 872% over growth media, 74.9% over Growth+Axitinib, and 1508%
over ZnCl2. For the same timepoint, Growth+Axitinib was 281% above insulin, 456%
above growth media, and 820% above ZnCl2; ZnCl2+Axitinib gene expression for grb10
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at 7 days was 55.4% lower than Growth+Axitinib and 74.5% lower than
Insulin+Axitinib.
Vegfr2 expression at the 4-day timepoint, when treated with Insulin+Axitinib, is
1490% elevated over insulin and 735% over growth media. ZnCl2+Axitinib- treated
Vegfr2 expression at this timepoint is decreased by 76.4% when compared to
Insulin+Axitinib. At 7 days, Insulin+Axitinib Vegfr2 gene expression is 768% over
ZnCl2, 437% over growth media, and 361% over insulin. Growth+Axitinib- treated gene
expression for Vegfr2 at 7 days is 586% above ZnCl2, 325% above growth media, and
265% above insulin; ZnCl2 expression is 82.1% below ZnCl2+Axitinib.
ZnCl2+Axitinib- treated expression of SOX9 at 1 day is 69% below ZnCl2; ZnCl2
expression is 124% above growth media. At 7 days, Growth+Axitinib treated ATDC5
chondrocytes’ gene expression is elevated by 747% over insulin, 684% over ZnCl2, and
480% over growth media. Runx1 gene expression in the qPCR experiment only yielded
statistically significant differential gene expression at the 7-day timepoint.
Insulin+Axitinib is elevated by 237% over growth media, 266% over ZnCl2, and 246%
over insulin. Growth+Axitinib is higher than growth media by 157%, ZnCl2 by 179%,
and insulin by 164%. ZnCl2+Axitinib expression for runx1 at 7 days is above ZnCl2 by
228%, growth by 202%, and insulin by 211%.
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Discussion
Bone fracture healing is a diverse field that often focuses on biological research
that aims to improve or understand bone fracture healing. More specifically, a facet of
this field focuses on improving patient healing outcomes for patients with diabetes that
impair normal bone healing. As a result, a substantial literature exists which describes
the role of insulin in both diabetic and normal healing. Studies such as Gandhi et. al
(2005) and Graves et. al (2011) have demonstrated using a diabetic fracture model that
insulin is necessary for proper bone healing. When non-diabetic or diabetic animals are
provided insulin at the fracture site, bone healing is improved (Cornish et. al, 1996).
Unfortunately, providing insulin to patients is problematic because insulin plays a major
role on regulating sugar levels; therefore, giving a patient insulin can affect sugar levels
causing side effects including swelling, weight gain, dizziness, moodiness, seizures, and
death. Therefore, some researchers have begun investigating whether insulin mimetics
such as ZnCl2 could promote bone healing in both non-diabetic and diabetic fracture
healing similarly to insulin. In fact, research has shown that treatment with ZnCl2 in a
non-diabetic (Wey et. al, 2014) and diabetic (Bortolin et. al, 2015) rodent fracture model
accelerate bone healing. Although, these positive results are promising, the mechanism
by which these insulin mimetics is not well understood. A better understanding of this
mechanism will be important to provide the best possible therapeutics for diabetic
patients. Our research focused on understanding the mechanism by which ZnCl2 affects
chondrogenesis, an important component of bone fracture healing.

50

Next Generation Sequencing showed that VEGFA and VEGFB gene expression
levels were consistent between both insulin and ZnCl2; however, only ZnCl2 treated
chondrocytes utilized flt1, the VEGFR1 receptor. This was further corroborated by
Ingenuity Pathway Analysis’ comparison analysis and canonical pathway analysis, which
demonstrated that VEGFR2 was significantly upregulated in ZnCl2 treated chondrocytes
when compared to insulin. IPA also demonstrated that the downstream regulators of
VEGFA & C and VEGFR1&2, Grb2 and c-Fos, were significantly elevated in ZnCl2
treated chondrocytes when compared to insulin. The NGS data also showed that jun and
junb were both significantly increased in both insulin and ZnCl2 treated chondrocytes, but
only jund was exclusively utilized by ZnCl2 treated chondrocytes. Due to increased levels
of grb2 in ZnCl2 treated ATDC5 cells, the data suggests that the Akt pathway may be
important to this mechanism. Burgess et. al demonstrated similar data in ATDC5 cells
that showed that ZnCl2 could lead to the upregulation of mTOR, an important factor in
the Akt pathway (Burgess et. al, 2017). Mukherjee and Rotwein have also shown that
Akt is crucial to bone healing using a histological sectioning method of mouse metatarsal
bones that were incubated ex vivo; their results show that inhibition of Akt activity leads
to impaired cartilage grown and impairments in osteoblast function and development
(Mukherjee and Rotwein, 2009).
The NGS data shows that ZnCl2 and insulin can also signal through overlapping
pathways. We demonstrated with NGS that runx3 was upregulated equally by both
insulin and ZnCl2, but neither had any statistically significant difference when compared
to the other. In the qPCR data, runx2 at 4-day and 7-day timepoints had no significant
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difference between insulin and ZnCl2 treatment when compared to growth media. Runx2
has been shown to regulate the gene network that is associated with insulin signaling
(Adhami et. al, 2011). Runx2 has also been demonstrated to accelerate fracture healing in
ZnCl2 (Wey et. al, 2014; Liu et. al, 2012).
When analyzing the effects of insulin and ZnCl2 on IGF-1 signaling canonical
pathway, insulin did not have a statistically significant Z score. However, ZnCl2 did
significantly elevate IGF-1 signaling. Zinc has been shown to signal through the insulin
pathway as both insulin and zinc were able to independently lead to the phosphorylation
of p38, GSK-3B, ERK1/2, Akt, and glucose oxidation (Norouzi et. al, 2018). Vanadium
sulfate has been shown to induce normoglycemia, prevent pancreatic islet atrophy, and
proliferate pancreatic beta cells as well as induce antilipolytic effects through Akt
activation, demonstrating its effects as an insulin mimetic (Pirmoradi et. al, 2016; Liu et.
al, 2013). Burgess has also demonstrated that ZnCl2 activated Akt as a component of its
insulin mimetic mechanisms (Burgess and Cottrell, 2017). On the other hand, this
demonstrates results that confirm the previous literature that ZnCl2 is an insulin mimetic,
as it is utilizing this pathway. Additionally, c-jun and c-fos downstream regulators of the
IGF-1 pathway are also elevated by ZnCl2 treated chondrocytes only. Induction of the
IGF-1 (Laron, 2001) and VEGF (Hu et. al, 2016) pathways has previously been shown to
increase cell proliferation and growth. As a result, the increases in proteoglycan
deposition and cell proliferation seen in our data may be a result of ZnCl2 induction of the
IGF-1 pathway. Burgess also demonstrated statistically significant increase in
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proteoglycan deposition in 100uM ZnCl2 treated ATDC5 cells at the 14 and 17-day
timepoints (Burgess and Cottrell, 2017).
When the VEGF pathway was inhibited in ZnCl2- or insulin-treated cells
significant decreases in proteoglycan deposition occurred on day 7 and 14 (P=0.007 for
ZnCl2, P=0.028 for insulin) when compared to controls. VEGF is known to be important
to vasculature development which is important for bone repair and chondrogenesis. Mice
with VEGF deficient osteoblast precursor cells cause an osteoporosis-like phenotype with
reduced bone mass and reduced osteoblast differentiation (Liu et. al, 2012). In a
Sprague-Dawley rat model where they received the VEGF inhibitor TNP-470, their
unilateral closed femoral fractures resulted in non-unions; this was due to the lack of
vasculature caused by the lack of VEGF due to the inhibitor; the rats that did not have
inhibition did not suffer adverse healing of their fracture (Keramaris et. al, 2008).
Our data demonstrates that at later timepoints, VEGF inhibition produces higher
amounts of genes such as jun, grb2, and cyclin D1 which were identified in the NGS data
and confirmed through QPCR. These mediators are all crucial for cell cycle progression,
cell proliferation, and cell growth. Jun and other AP-1 members have been demonstrated
to increase chondrocytes to become hypertrophic through contributing to Sox9’s actions
(He et. al, 2016). Cyclin D1, as stimulated by TGF-β, aids in chondrocyte maturation and
proliferation (Li et. al, 2006); our results from the NGS experiment demonstrate an
increase in the TGF- β family as well.
Our data also demonstrated that ZnCl2 significantly increases the expression of
various collagen genes as well as BMP6. These genes are crucial for cartilage matrix
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formation and bone formation. Collagen 17a1 is a component of epithelial and
mesenchymal interactions, two types of tissue that rely on matrix interactions. Col17a1
deficiency, as demonstrated through a collage 17 knock out mouse model and a collagen
17 rescue model, causes diminished levels of iron deposition, delayed calcification, and
enamel hypoplasia (Asaka et. al, 2009). BMP6 is a growth factor that has been shown to
enhance chondrogenesis in marrow stromal cells; the cells being treated with BMP also
had higher proteoglycan staining results (Sekiya et. al, 2001), as seen in this research. We
believe that ZnCl2 upregulating many members of the collagen family and BMP6, which
insulin is not, is a component of its success as an insulin mimetic in bone healing.
Runx1 is not usually thought of as a key mediator in bone healing. Most research
demonstrates that runx2 is essential for bone development. However, in the NGS
experiment, only ZnCl2 chondrocytes upregulated the runx1 gene not runx2. Burgess also
found that there were no significant differences in runx2 expression when comparing
treatment groups over time (Burgess and Cottrell, 2017). However, our qPCR gene
expression data showed that runx2 had decreased expression in chondrocytes treated with
ZnCl2 and VEGF inhibitor when compared to ZnCl2 alone. However, runx1 was
significantly elevated in ZnCl2+VEGF inhibitor as compared to ZnCl2 alone. This data
suggests that in the presence of a VEGF that runx1 may be an important mediator in
ZnCl2- mediated chondrogenesis.
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Conclusions
Bone formation can be aided by both ZnCl2 treatment and insulin treatment.
Although the mechanisms by which ZnCl2 and insulin have been shown to overlap, our
data suggests that ZnCl2 works through a mechanism different then insulin when
employing the VEGF- pathway. Future studies could include quantifying protein
expression to determine if these gene expression patterns are similar at the protein level.
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Appendix 1
Sample Name and

A260/A280

Concentration (ug/uL)

Growth Media 1 Day 1

2.019

0.546ug/uL

Growth Media 2 Day 1

2.013

0.773

Growth Media 3 Day 1

2.029

0.733

Insulin 1 Day 1

2.016

0.834

Insulin 2 Day 1

2.036

0.903

Insulin 3 Day 1

2.026

0.928

ZnCl2 1 Day 1

2.023

0.243

ZnCl2 2 Day 1

2.042

0.245

ZnCl2 3 Day 1

2.029

0.273

Growth Media 1 Day 4

2.040

0.230

Growth Media 2 Day 4

2.044

0.398

Growth Media 3 Day 4

2.039

0.370

Insulin 1 Day 4

2.051

0.365

Insulin 2 Day 4

2.045

0.420

Insulin 3 Day 4

2.036

0.393

ZnCl2 1 Day 4

2.008

0.228

ZnCl2 2 Day 4

2.029

0.314

ZnCl2 3 Day 4

2.047

0.308

Growth Media 1 Day 7

1.992

0.333

Timepoint
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Growth Media 2 Day 7

2.058

0.506

Growth Media 3 Day 7

2.065

0.408

Insulin 1 Day 7

2.053

0.511

Insulin 2 Day 7

2.046

0.393

Insulin 3 Day 7

2.051

0.507

ZnCl2 1 Day 7

2.050

0.364

ZnCl2 2 Day 7

2.054

0.394

ZnCl2 3 Day 7

2.048

0.400

Growth Media and 1uM

2.017

0.611

2.028

0.672

2.029

0.693

2.022

0.758

2.033

0.795

2.037

0.853

2.022

0.177

2.026

0.251

2.014

0.202

Axitinib 1 Day 1
Growth Media and 1uM
Axitinib 2 Day 1
Growth Media and 1uM
Axitinib 3 Day 1
Insulin and 1uM Axitinib 1
Day 1
Insulin and 1uM Axitinib 2
Day 1
Insulin and 1uM Axitinib 3
Day 1
ZnCl2 and 1uM Axitinib 1
Day 1
ZnCl2 and 1uM Axitinib 2
Day 1
ZnCl2 and 1uM Axitinib 3
Day 1
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Growth Media and 1uM

2.023

0.462

2.021

0.472

2.028

0.477

2.031

0.355

2.035

0.390

2.036

0.318

2.048

0.233

2.013

0.321

2.014

0.270

2.044

0.533

2.048

0.499

2.051

0.445

2.043

0.365

2.049

0.384

Axitinib 1 Day 4
Growth Media and 1uM
Axitinib 2 Day 4
Growth Media and 1uM
Axitinib 3 Day 4
Insulin and 1uM Axitinib 1
Day 4
Insulin and 1uM Axitinib 2
Day 4
Insulin and 1uM Axitinib 3
Day 4
ZnCl2 and 1uM Axitinib 1
Day 4
ZnCl2 and 1uM Axitinib 2
Day 4
ZnCl2 and 1uM Axitinib 3
Day 4
Growth Media and 1uM
Axitinib 1 Day 7
Growth Media and 1uM
Axitinib 2 Day 7
Growth Media and 1uM
Axitinib 3 Day 7
Insulin and 1uM Axitinib 1
Day 7
Insulin and 1uM Axitinib 2
Day 7
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Insulin and 1uM Axitinib 3

2.046

0.371

2.048

0.202

2.059

0.465

2.047

0.515

Day 7
ZnCl2 and 1uM Axitinib 1
Day 7
ZnCl2 and 1uM Axitinib 2
Day 7
ZnCl2 and 1uM Axitinib 3
Day 7
Table 7: RNA quality and concentration analysis.
Appendix 2

Figure 11: Cellular Proliferation in ATDC5 Cells at 48hours Post Axitinib Treatment
Dose Dependent Response in an MTT Assay.
This figure demonstrates treatment groups ZnCl2 (ZN), insulin (INS), and growth
media (CON) and their cellular proliferation after being exposed to various doses of
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Axitinib. A vertical line at 100% shows the proliferation rate of cells without Axitinib. In
this figure, every dosage of the Axitinib caused a statistically significant decrease in
cellular proliferation except for ZnCl2 0.01uM.
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